What stage does Deerfield Management Company invest at?

Deerfield Management Company invests at the Growth, Late Stage stages.

What sectors does Deerfield Management Company focus on?

Deerfield Management Company focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.

Where is Deerfield Management Company located?

Deerfield Management Company is headquartered in New York, US.

Does Deerfield Management Company lead rounds?

Deerfield Management Company has led 3 of the 3 rounds where its role is on record.

Deerfield Management Company

Venture capital

New York · Growth–Late Stage · 88 people tracked

Also known as DEERFIELD MANAGEMENT COMPANY, L.P.

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Deerfield advances healthcare through the combination of investment, information, and philanthropy. It provides flexible funding models to companies spanning the healthcare ecosystem and applies AI, data, and market research to drive healthcare technology and innovation. The firm builds companies independently and alongside strategic partners, forming alliances with research institutions and technology companies. Its New York City-based not-for-profit foundation supports innovative healthcare initiatives, reflecting a broad approach that blends capital, information services, and charitable activity across the sector.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Medical Devices New York New York City United States

Source: firm website, verified Aug 25, 2026.

Stage

Growth–Late Stage

New York, NY, US

Instruments

Equity

Founded

1994

Last 12 months

2 investments

AUM

$19.1B

Tracked investments

Team · 88 people

from the firm's website & public directories

Alexis Cazé· President of the Deerfield Foundation· New York, New Yorkin

Alexis Cazé is President of the Deerfield Foundation and joined Deerfield Management in 2006, where he previously held roles including Managing Director of the Deerfield Institute, Chief Information Officer, and Chief Operating Officer. In his current role he works on expanding the Foundation's nonprofit efforts. Before Deerfield, he worked at Gerson Lehrman Group, Sanofi, and PricewaterhouseCoopers, and he holds a PharmD from the Paris University of Pharmacy and an MSc in Business from E.M. Lyon Business School.

Andrew ElBardissi· Partner· New York, New Yorkin 𝕏

A partner on Deerfield's Medical Technologies team who joined in 2017, previously a principal at Longitude Capital investing in medtech and biotech and an associate in JPMorgan's healthcare investment banking practice. He is a trained surgeon with an M.D. from the Mayo Clinic, an M.P.H. and M.B.A. from Harvard, and residency training at Harvard's Brigham and Women's Hospital and Stanford.

Brian Bizoza· Partner· New York, New Yorkin

Partner at Deerfield who joined in 2012, overseeing public fund processes and conducting research on healthcare companies. Previously a portfolio manager at S Squared Technology, an analyst at Amaranth Advisors, and an equity analyst at Lehman Brothers and Lazard Frères. Holds a B.A. from Johns Hopkins and an M.D. from SUNY Syracuse.

Julian Harris· Partner· New York, New York

Konstantinos Aprilakis· Partner· New York, New Yorkin

Partner on Deerfield's Therapeutics team since 2021, focused on research and analysis of healthcare companies. Previously a biotech research analyst, including as Managing Director at Stifel, Director at Deutsche Bank, and VP at JMP Securities, and earlier a biomedical researcher. Holds a B.A. from Stony Brook and an M.D. from Weill Cornell.

Terence Fox-Karnal· Partner and Head Equity Linked and Credit Trader· New York, New York, United Statesin

Terence Fox-Karnal joined Deerfield in 2010 and works on the Public Structured Finance team, providing analytical and structuring services. He previously was a volatility trader at BAM Capital and a partner trading healthcare-sector equity derivatives at TORO Trading, and holds an S.B. in Finance and Economics from MIT.

Abraham Kometz· Partner· New York, New Yorkin 𝕏

Adam Greene· Partner· New York, New Yorkin

Cameron Wheeler· Partner· New York, New Yorkin

Elise Wang· Partner· New York, New Yorkin

Howard Furst· Partner· New York, New Yorkin

Jason Fuller· Partner· New York, New Yorkin 𝕏

Jonathan Leff· Partner· New York, New York

Leslie Henshaw· Partner· Brooklyn, New Yorkin

Narendra Nayak· Partner· New York, New Yorkin

Nicholas Bishop· Partner, Therapeutics team· New York, New Yorkin

Nicholas Bishop is a Partner on Deerfield's Therapeutics team, which he joined in 2014, focusing on research and analysis of companies in the healthcare industry. He previously spent four years as a biotechnology research analyst at Cowen and Company and worked as a biomedical research scientist at Harvard University and MIT. He holds a B.A. with honors from Rice University and a Ph.D. from MIT, and has published scientific articles on the genetic regulation of aging and lifespan.

Peter Steelman· Partner· New York, New Yorkin

Sumner Anderson· Partner, Public Structured Finance team· New York, New Yorkin

Sumner Anderson is a Partner on Deerfield's Public Structured Finance team, which he joined in 2019 after starting at the firm in 2012 on the Therapeutics team analyzing healthcare companies. Before Deerfield, he was a pharmaceuticals research analyst at Millennium Management, a Managing Director in healthcare investment banking at Wells Fargo Securities, and a pharmaceutical analyst at Citadel Investment Group. He earned an A.B. in History and Economics from Harvard University and an M.B.A. in Finance and Accounting from New York University.

Terence Karnal· Partner· New York, New York

Vincent Mellet· Partner· New York, New Yorkin

Katherine Lazar· Principal, Investment Strategy

Bharath Ganesan· Principal· New York, New Yorkin

Gilan Megeed· Principal· New York Cityin

Jackson Harvey· Principal· New York, New Yorkin 𝕏

Steve Anastos· Principal· New York, New Yorkin 𝕏

Veranika Razhkova· Principal· New York, New Yorkin 𝕏

Wenxi Chen· Principal· New York, New Yorkin

Abdul Khan· Senior Director, Biologics· Bronx, New York, United Statesin

Adriana Brito· Desktop Support Engineer

Adriana Brito joined Deerfield in 2024 as a Desktop Support Engineer. She previously worked as a Senior Help Desk Engineer consultant at GIC Private Limited and spent nearly three years at Best Buy, most recently as a Microsoft Expert. She holds a B.S. in Computer Science from New Jersey City University.

Alex Lachapelle· Director, Product and Strategy

Alexander Ashavsky· Managing Director, Data Science and Engineering· New York, New York, United Statesin

Alex Ashavsky joined Deerfield in 2018 and serves as a Managing Director on the Deerfield Intelligence team, focusing on data science and engineering. He previously held senior software engineering roles at MediaRadar and iHeartMedia, worked as a business intelligence consultant at Sky IT Group, and began his career at TransPerfect Legal Solutions.

Angela Asencio· Manager, Therapeutics Team· Harrison, New York, United Statesin

Angela Asencio joined Deerfield in 2015 and serves as a Manager on the Therapeutics Team, focusing on business operations and administration. She previously worked as an executive assistant at Barclays and AmeriFactors Financial Group, and held various roles at North Eastern Asset Recovery. She holds a B.A. in Economics from SUNY Albany.

Anthony Barsotti· Senior Director, Preclinical Pharmacology

Anthony Barsotti is a Senior Director of Preclinical Pharmacology at Deerfield Discovery and Development, joining the firm in 2020. He previously held research roles at Inzen Therapeutics, Kadmon Corporation, and Pfizer, and holds a B.A. from the University of Pennsylvania and a Ph.D. from Columbia University.

Brandon Gaitan· Director, Product & Strategy

Carly Filmanski· Executive Assistant

Executive Assistant supporting Deerfield's Medical Technologies team, joining the firm in 2025. She previously held executive and administrative roles at KBW, Viking Global Investors, Millennium Management, and other firms, and holds a B.A. in Visual and Media Arts from Emerson College.

Carolyn Cassell· Executive Assistant· United Statesin

Executive Assistant supporting the Human Resources team at Deerfield, joining in 2026. Previously an Administrative Assistant at The Raine Group and a Multi-Grade Learning Specialist at Classical Charter Schools; holds a B.S. in Psychology and Child Studies from Santa Clara University.

Christine Brideau· Vice President, Preclinical Pharmacology, Deerfield Discovery and Development

Christine Brideau joined Deerfield in 2019 and leads preclinical pharmacology within Deerfield Discovery and Development. She previously served as VP of In Vitro Pharmacology at WuXi AppTec and spent 24 years at Merck, and has co-authored over 40 peer-reviewed publications.

Christopher Freeland· Counsel, Portfolio Company Operations· New York, New York, United Statesin

Christopher Freeland joined Deerfield in 2019 as Counsel for Portfolio Company Operations, supporting the firm's External Operations team. He previously served as General Counsel and COO at Aralez Pharmaceuticals, was Associate General Counsel at AIG, and began his career as a corporate associate at Willkie Farr & Gallagher and as an investment banking analyst at Citigroup. He holds an A.B. from Princeton and a J.D. from the University of Virginia.

Christopher Jean-Pierre· Systems Engineer

Coco Dong· Director, Quantitative Applications· Yonkers, New York, United Statesin

Coco Dong, Ph.D. is a Director of Quantitative Applications on the Deerfield Intelligence team, having joined Deerfield in 2020 as a Senior Genetic Data Scientist before moving to the Intelligence team in 2023. She previously worked as a strategist at Goldman Sachs and a principal statistician at GlaxoSmithKline, and holds an M.S. in Computer Science and a Ph.D. in Biostatistics from USC.

Daniel Glass· Managing Director, Global Market Research· New York City Metropolitan Areain

David Greenwald· Managing Director· New York City Metropolitan Areain

Dharan Kadiyala· Associate Director, Market Research· New York City Metropolitan Areain

Edi Assis· Director, Cloud Platform Engineering

Edi Assis is a Director of Cloud Platform Engineering on Deerfield's IT team, joining in 2026. Previously held platform, cloud, and infrastructure engineering leadership roles at Soros Fund Management, Autonomy Capital Management, AQR Capital Management, and Pine River Capital Management, and holds a B.S. in Computer Information Systems from Brooklyn College.

Elizabeth Baer· Senior Associate, Investor Business Development

Elizabeth Baer joined Deerfield in 2022 as an Executive Assistant and now serves as Senior Associate for Investor Business Development. She previously worked as an administrative assistant at C & R Management Company in Salt Lake City and holds a B.S. in Business Administration from Babson College.

Elizabeth Dugan· Director, Project Management

Elizabeth Dugan, Ph.D., is a Director of Project Management on the Deerfield Discovery and Development team who joined in 2026. She previously spent over five years at PsychoGenics and over seven years at The Miami Project to Cure Paralysis, and holds a B.S. in Psychology from the University of Florida and a Ph.D. in Neuroscience from Drexel University College of Medicine.

Emily Boylan· Associate Director, Market Research

Emily Boylan is an Associate Director of Market Research on the Deerfield Intelligence team, joining the firm in 2018. She previously conducted survey research at GfK and holds a B.A. in Sociology from the University of San Francisco and an M.St. in the Study of Religion from the University of Oxford.

Emma Gigerenich· Senior Director, Applied Epidemiology

Eric Feuer· Senior Compliance Officer & Counsel· New York City Metropolitan Areain

Eric Feuer joined Deerfield in 2021 as a Senior Compliance Officer and Counsel. He previously spent seven years in compliance at Apollo Global Management and earlier worked in compliance at J.P. Morgan Chase's Corporate & Investment Bank. He holds a B.A. from Binghamton University and a J.D. from Cardozo School of Law.

Gabrielle Briganti· Communications Associate· New York, New York, United Statesin

Gabrielle Briganti is a Communications Associate who joined Deerfield in 2023 as an Executive Assistant. She previously spent over two years at SL Green Realty Corp., most recently as Executive Assistant to the COO, and holds a B.S. in Business Administration from the University of Richmond.

Gopal Kotecha· Director, Quantitative Research

Harold Davidson· Senior Transactions Counsel

Harold Davidson joined Deerfield in 2025 as Senior Transactions Counsel, working in business operations, legal, and compliance. He previously was a Corporate Partner at Katten Muchin Rosenman for over two years and a Partner at McDermott Will & Emery for over 15 years. He holds a B.A. in Political Science from Emory University and a J.D. from NYU School of Law.

Helena Howard· Compliance Associate· New York City Metropolitan Areain

Hsueh-Cheng Huang· Senior Director, Preclinical Pharmacology

Jared Anderman· Managing Director, Data Analytics· New York, New York, United Statesin

Jared Anderman is a Managing Director, Data Analytics on the Deerfield Intelligence team, joining the firm in 2010. He previously worked as a compensation analyst at Bloomberg LP/Geller & Co. and Cantor Fitzgerald, and began his career at JPMorgan Chase; he holds a B.S. in Marketing from the University of Delaware.

Jennifer Hsieh· Director, Compliance· New York, New York, United Statesin

Jessica Sagers· Communications Inquiries contact· Washington DC-Baltimore Areain

Contact for communications inquiries at Deerfield.

j•••@deerfield.comreveal

Jinho Jang· Director, Quantitative Research· New York, New York, United Statesin

Jonathan Isler· Partner and Chief Financial Officer, Funds· New York, New York, United Statesin

Karen Arnone· Chief Property and Development Officer

Karen Arnone joined Deerfield in 2005 and serves as Chief Property and Development Officer, overseeing the development and operations of the firm's healthcare innovation center at 345 Park Avenue South. She previously served as Deerfield's Chief Administrative Officer and led its HR function, and earlier held administrative roles at Balyasny Asset Management and XL Reinsurance.

Karen Heidelberger· Partnership Inquiries contact· Greenwich, Connecticut, United Statesin

Contact for partnership inquiries at Deerfield.

k•••@deerfield.comreveal

Kevin Goncalves· Senior Director, Preclinical Pharmacology

Maria Guglielmo· Manager, Recruiting and Employee Experience· Yonkers, New York, United Statesin

Marissa Carnevale· Director of Talent Acquisition, Portfolio Company Operations

Carnevale joined Deerfield in 2018 and works on the External Operations team focusing on talent acquisition for portfolio companies. She previously held talent and recruiting roles at Johnson & Johnson, Bristol-Myers Squibb, The Judge Group, Taratec Development Corporation, SRG Woolf Group, and Kelly Scientific Resources, and holds a B.S. in Biology from Binghamton University.

Mellissa Gray· Senior Scientist, Protein Sciences· New York, New York, United Statesin

Michael Cingolani· Associate Director, Cybersecurity

Cybersecurity associate director who joined Deerfield in 2022, previously an Information Security Analyst at Disney Streaming Services for four years and earlier a security operations analyst at BASF. Holds a B.S. in Business and Information Systems from New Jersey Institute of Technology.

Michael Farrell· Head of Portfolio Company Operations· New York City Metropolitan Areain

Michael Farrell leads Portfolio Company Operations on Deerfield's External Operations team, joining in 2016 as an Operations Executive overseeing investments in the firm's Private Design and Healthcare Innovations Funds. He previously held senior finance roles including VP of Finance at Amarin Corporation and controller/accounting positions at several pharmaceutical companies, and began his career at Arthur Andersen as a CPA.

Michael Hurley· Managing Director

Nicholas Dow· Director, Software Engineering· Mumbai Metropolitan Regionin

Nicholas Dow is a Director of Software Engineering on the Deerfield Intelligence team, having joined the firm in 2026. He previously worked as a Machine Learning Engineer at Delta Global Management and began his career as a Quant Developer at Wells Fargo Securities, and holds a B.A. in Statistics and Computer Science from Harvard College.

Nicolas Jbeyli· Head of Strategy and Operations

Nicole Layton· Senior Associate, Investor Relationship Management· New York City Metropolitan Areain

Oleg Laptenko· Principal Scientist, Preclinical Pharmacology· Bronx, New York, United Statesin

Pooja Deo· Senior Director, Business Intelligence· New York, New York, United Statesin

Senior Director on the Deerfield Intelligence team, joined the firm in 2021. Previously worked in business intelligence and data analyst roles at Guidepoint, Outcome Health, New Jersey Parent Caucus, and L&T InfoTech in India. Holds a B.E. in Computer Science from the University of Pune and an M.S. in Information Systems from Stevens Institute of Technology.

Raheleh Hatami· Senior Director, Portfolio Strategy and Innovation

Roberto Herrera· Associate Director, Solutions and Support Manager· Middletown, New York, United Statesin

Rodrigo Ceballos· Director, AI Engineering

Director of AI Engineering on the Deerfield Intelligence team who joined in 2025. Previously spent three years at Georgian (most recently AI Tech Lead) and worked at Paige AI as a Senior AI Engineer; holds a B.S. from NYU Abu Dhabi and an M.S. in Neural Systems and Computation from ETH Zurich.

Sabrina Khanum· Desktop Support Engineer

Sam Galindo· Director, Innovation Alliances

Scott Donohue· Senior Director, Market Access· New York City Metropolitan Areain

Scott Donohue is a Senior Director, Market Access on the Deerfield Intelligence team, joining in 2023. He previously held roles at IQVIA, TG Therapeutics, and Bristol Myers Squibb in the healthcare industry. He holds a B.A. from Colgate University and an M.P.A. in Health Policy and Management from New York University.

Susanna Hall· Senior Director of Data Integrity and Operations

Susannah Barbee· Vice President, Translational Immunology· New York, New York, United Statesin

Vice President of Translational Immunology within Deerfield Discovery and Development, having joined Deerfield in 2024. She previously held translational biology and immuno-oncology research leadership roles at TRex Bio, Five Prime Therapeutics, and Amplimmune, and holds an A.B. from Harvard and a Ph.D. in Biology from Caltech.

Tatsuya Kano· Senior Project Manager, IT

Victoria Gaddy· VP, Portfolio Company Operations HR & Strategy

Alison Stamas· Associate· New York, New Yorkin

Crystal Wright· Associate· New York, New Yorkin

Eddie Yang· Analyst· New York, New Yorkin

James Flynn· Managing Partner· New York, New Yorkin

Talia Askowitz· Principal· New York, New Yorkin

Talia Askowitz is a Principal on the Healthcare Services team at Deerfield Management, where she focuses on early and growth stage healthcare technology and services investments. She joined the firm in 2020. She earned a B.A. in Human Biology from the City University of New York's Macaulay Honors College, graduating Phi Beta Kappa and summa cum laude.

What they invest in

from 34 of 39 portfolio companies

Healthtech ×23Biotech ×17Medical Devices ×13Digital Health ×8AI & Machine Learning ×5Deep Tech ×2Hardware ×2SaaS ×2

HQs:United States×32

Investments · 39 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 2 2024 · 3 2022 · 6 2021 · 1 2020 · 5 2019 · 2 2018 · 2 2017 · 2 2016 · 1 2015 · 127 dated

NXT Biomedicalnxtbiomedical.comMay 2021✓ verified

NXT Biomedical is a medical device incubator that develops and spins out startups building clinical medical technologies aimed at addressing unmet needs and reducing healthcare costs.

BiotechHealthtechMedical DevicesIrvine, US

Stanton Rowe(CEO)Don Bobo(Director)

BoardKadhiresan V Kadir(Director)Steven Hochberg(Director)Andrew Cleeland(Director)

Board seatAndrew ElBardissi· per SEC Form D

Aloalosolutions.com in✓ verified

Alo is a physician enablement platform offering practice management, financial strategy, and value-based care services to independent physicians managing the business of their practices.

Digital HealthHealthtechSaaS

Matt Eirich(CEO)

Pleno Inc.plenoinc.com✓ verified

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsForesite Capital Medical Excellence Capital

Spectrawavespectrawave.com in 𝕏May 2019✓ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)Guillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)Jeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)

Co-investorsLumira Ventures S3 Ventures SV Health Investors Johnson & Johnson Innovation – JJDC

Acutus Medicalacutusmedical.comJul 2022

HealthtechCarlsbad, US

Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)John Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Board seatAndrew ElBardissi· per SEC Form D

Co-investorsAdvent Life Sciences OrbiMed GE Ventures Index Ventures

Adelabioadelabio.com in 𝕏Jul 2025

Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.

BiotechDigital HealthHealthtechFoster City, US

Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)

Board seatAndrew ElBardissi· per SEC Form D

Co-investorsDecheng Capital F-Prime Capital OrbiMed Menlo Ventures

Appello Pharmaceuticalsappellopharma.comJan 2022SEC filingmedium confidence

Appello Pharma is a biopharmaceutical company focused on drug discovery and development for neurological and metabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesNashville, US

Dr. Laden(Co-founder)Christopher Rand(Executive Officer)Vaughn Bryson(Director)Jeff P. Conn(Director)

BoardWilliam Slattery(Director)Howie Furst(Director)in

Board seatHoward Furst· per SEC Form D · $13.5M raise · filed Jan 2022

Co-investorsMountain Group Capital Relevance Ventures

Aprecia PharmaceuticalsJan 2016SEC filingmedium confidence

BiotechLanghorne, US

Donald Wetherhold(Executive Officer)Michael Rohlfs(Executive Officer)David Furniss(Executive Officer)Robert Williford(Executive Officer)

BoardLawrence Glassmann(Director)James Evans(Director)

Board seatJonathan Leff· per SEC Form D · $84M raise · filed Jan 2016

Audentes Therapeuticsastellasgenetherapies.com inAug 2015SEC filingmedium confidence

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)

BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)Thomas Woiwode(Director)

Board seatJonathan Leff· per SEC Form D · filed Sep 2015

Co-investorsAsset Management Company RA Capital venBio Partners OrbiMed Venrock

Aurion Biotechaurionbiotech.com inApr 2022SEC filingmedium confidence

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.

BiotechHealthtechMedical DevicesSeattle, US

DAVID ROSTOV(Executive Officer)GREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)

Board seatAndrew ElBardissi· per SEC Form D · $26.1M raise · filed Apr 2022

Co-investorsVisionary Ventures Flying L Partners

Axon Therapiesaxontherapies.comJan 2019SEC filingmedium confidence

Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).

HealthtechMedical DevicesNew York, US

Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)

BoardPaul LaViolette(Director)in

Board seatAndrew ElBardissi· per SEC Form D · $15M raise · filed Feb 2019

Co-investorsSV Health Investors

Conventus OrthopaedicsApr 2017SEC filingmedium confidence

HealthtechMaple Grove, US

Michael Brenzel(Executive Officer)Paul Buckman(Executive Officer)Kent Lind(Executive Officer)John Feriancek(Executive Officer)Paul Hindrichs(Executive Officer)David Blue(Executive Officer)

Board seatAndrew ElBardissi· per SEC Form D · $5M raise · filed Jan 2019

Dracenpharmadracenpharma.comJan 2018SEC filingmedium confidence

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

BoardRobert Jackson(Director)

Board seatJonathan Leff· per SEC Form D · $40.5M raise · filed Jan 2018

Co-investorsBiotech Investments S.R.O OUP (Osage University Partners)

Element Sciencemyjewel.com inMar 2020SEC filingmedium confidence

Jewel is a wearable patch cardioverter defibrillator designed to provide continuous protection from sudden cardiac arrest, using machine learning to minimize false alarms while requiring no daily maintenance for up to a week.

AI & Machine LearningHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)

BoardRussell Hirsch(Director)Neil Exter(Director)inKrishna Yeshwant(Director)inWilliam H. Kucheman(Director)William Kucheman(Director)

Board seatAndrew ElBardissi· per SEC Form D · $145.6M raise · filed Mar 2020

Co-investorsThird Rock Ventures GV (Google Ventures)

Elion Therapeuticseliontx.com inJun 2024SEC filingmedium confidence

Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.

BiotechNew York, US

Kieren Marr(Executive Officer, Director)

BoardJim Flynn(Director)Martin Heidecker(Director)in

Board seatJonathan Leff· per SEC Form D · $83.8M raise · filed Jun 2024

Co-investorsAMR Action Fund Illinois Ventures

Humanity Health, Inc.Jul 2022SEC filingmedium confidence

New York, US

Kathryne Cooper(Director)Ronald Mitchell(Executive Officer, Director)Jonathan Ramos(Executive Officer)

BoardMichael Farrell(Executive Officer)in

Board seatBharath GanesanJulian Harris· per SEC Form D · $11M raise · filed Jul 2022

InCarda Therapeuticsincardatherapeutics.com inOct 2020SEC filingmedium confidence

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.

BiotechDigital HealthMedical DevicesBrisbane, US

Rangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)Miller Samantha(Executive Officer)Carlos A. Schuler(Executive Officer, Director)John S. Patton(Executive Officer, Director)

BoardMcCarthy Reenie(Director)

Board seatAndrew ElBardissi· per SEC Form D · $50M raise · filed Oct 2020

Co-investorsAsset Management Company HealthCap Sofinnova Ventures

InnervaceAug 2022SEC filingmedium confidence

BiotechNew York, US

Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)

BoardDavid Greenwald(Director)in

Board seatJonathan Leff· per SEC Form D · $40M raise · filed Aug 2022

Co-investorsBioAdvance

Iowa ApproachMay 2018SEC filingmedium confidence

BiotechIowa City, US

Steven Richard Mickelsen(Executive Officer, Director, Promoter)Raju Viswanathan(Executive Officer)David Jacques(Executive Officer)Allan Zingeler(Executive Officer, Director)

BoardDavid Booth(Director)Howard Dittrich(Director)

Board seatAndrew ElBardissi· per SEC Form D · $12M raise · filed Aug 2018

Co-investorsCadence Healthcare Ventures

Medical Micro Instrumentsmmimicro.com in 𝕏Mar 2024SEC filingmedium confidence

MMI develops the Symani Surgical System, a robotic platform with NanoWrist instruments designed for microsurgery and supermicrosurgery, enabling surgeons to perform delicate procedures such as dissection and anastomosis.

HealthtechMedical DevicesRoboticsJacksonville, US

Mark Toland(Executive Officer, Director)Andrew Cleeland(Director)Justin Lynch(Director)Theresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)

Board seatAndrew ElBardissi· per SEC Form D · $110M raise · filed Mar 2024

Co-investorsAndera Partners Corewell Health Ventures Fountain Healthcare Partners

Neochordneochord.com in 𝕏Nov 2022SEC filingmedium confidence

NeoChord develops a medical device system for beating heart mitral valve repair in patients with mitral valve regurgitation.

Advanced ManufacturingHealthtechMedical DevicesMaple Grove, US

Todd Berg(Executive Officer, Director)David H. Chung(Executive Officer, Director)Ron Nelson(Executive Officer)

BoardCasey Tansey(Director)Mudit K. Jain(Director)

Board seatAndrew ElBardissi· per SEC Form D · $6M raise · filed Nov 2022

Co-investorsTreo Ventures, Llc US Venture Partners

Perfect HealthSep 2020SEC filingmedium confidence

HealthtechWoburn, US

Alan Abrams(Executive Officer, Director)Vince Cook(Executive Officer)Peter Dunphy(Executive Officer, Director)Douglas Thompson(Executive Officer, Director, Promoter)Craig Bass(Executive Officer)Jennifer Bryant(Executive Officer)

Board seatSteve AnastosJulian Harris· per SEC Form D · $45M raise · filed Sep 2020

Reprieve Cardiovascularreprievecardio.comAug 2020

Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.

Digital HealthHealthtechMedical DevicesMilford, US

Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)Mark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)

Board seatAndrew ElBardissi· per SEC Form D

Co-investorsArboretum Ventures Lightstone Ventures Rex Health Ventures Genesis Venture Capital Sante Ventures

Springtide Child DevelopmentOct 2020SEC filingmedium confidence

HealthtechTrumbull, US

Jia Jia Ye(Executive Officer, Director)Alexa Rachlin(Director)Missy Krasner(Director)

Board seatSteve AnastosJulian Harris· per SEC Form D · $18.1M raise · filed Nov 2020

About Neomorphneomorph.com in 𝕏

Neomorph develops molecular glue degraders designed to target and degrade disease-causing proteins through engineered neomorphic protein surfaces.

BiotechDeep Tech

Co-investorsLongwood Fund

Cohere Healthcoherehealth.com inFeb 2024 · $50M

Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US

Siva Namasivayam(Executive Officer, Director)Robert Shepardson(Executive Officer)Kristen Carucci(Executive Officer)Duncan Reese(Executive Officer)

BoardDavid Barrett(Director)Amir Debourou(Director)

Co-investorsCota Capital Flare Capital Partners Longitude Capital Define Ventures Flare Capital Strategies Temasek

Deerfield Catalystdfcatalyst.com in

Deerfield Catalyst is a medtech incubator that develops medical technology solutions aimed at improving patient outcomes and care delivery.

HealthtechMedical Devices

Encodiaencodia.comDefunct

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARCH Venture Partners Decheng Capital Alexandria GV (Google Ventures)Nan Fung Life Sciences Northpond Ventures

Frontier Medicinesfrontiermeds.com in 𝕏Aug 2025 · $80M

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.

AI & Machine LearningBiotechSouth San Francisco, US

Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)

Co-investorsBerkeley Catalyst DCVC (Data Collective)Droia Ventures MPM BioImpact RA Capital DCVC Bio

Homology Medicineshomologymedicines.comJul 2017

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners OUP (Osage University Partners)Alexandria HBM Healthcare Investments Maverick Ventures +4 more

Liquid Wire

Portland, US

Robert Gunn(Executive Officer, Director)Scott Fournier(Executive Officer)Mark Ronay(Executive Officer, Director)

BoardKaren Y. Spencer(Director)Jon C. Ohrn(Director)John Brewer, Jr.(Director)

Shineshinetext.comFeb 2026

Brooklyn, US

Marah Lidey(Executive Officer, Director)Naomi Hirabayashi(Executive Officer, Director)

BoardVictoria Song(Director)

Co-investorsComcast Ventures LaunchCapital Fidelity Investments Oaktree Sumitomo Corporation

SHINE Medical Technologiesshinemed.com

HealthtechJanesville, US

Gregory Richard Piefer(Executive Officer, Director)Katrina Pitas(Executive Officer)Darin Janecek(Executive Officer)Anton Asmuth(Executive Officer, Director)James Costedio(Executive Officer)David A. Weissburg(Executive Officer, Director, Promoter)

Co-investorsVenture Management Wisconsin Investment Partners

Somatussomatus.com in

Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.

Digital HealthHealthtechMclean, US

Ikenna Okezie(Executive Officer, Director)Alexander Houlday(Executive Officer)Stacey Queen-Pyndell(Executive Officer)

BoardAnna Haghgooie(Director)Anthony Welters(Director)

Co-investorsFlare Capital Partners Optum Ventures HealthQuest Capital Blue Venture Funds Defy Partners Longitude Capital +4 more

Soonsoon.app in 𝕏Feb 2026 · $240M

Soon is a portfolio management platform that automates buying and selling of assets across multiple exchanges using strategies like dollar-cost averaging and tax-loss harvesting.

Crypto & Web3FintechSalt Lake City, US

Michael Shattuck(Founder)in

Co-investorsY Combinator Fidelity Investments Oaktree

Strata Oncologystrataoncology.com in 𝕏

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in

Co-investorsArboretum Ventures Pfizer Venture Investments Merck Global Health Innovation Fund Pfizer Ventures

Synthekinesynthekine.com in 𝕏

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapital The Column Group Bain Capital Life Sciences Canaan Partners RA Capital TCG Crossover +2 more

Trivascularendologix.com in 𝕏

Endologix develops endovascular medical devices for treating vascular conditions such as abdominal aortic aneurysms and peripheral arterial disease in the femoropopliteal arteries.

HardwareHealthtechMedical Devices

John Liddicoat(President and Chief Executive Officer)Graham Phillips(Chief Operating Officer)Cindy Pinto(Chief Financial Officer)Jorge O'Hara(Chief Commercial Officer)

Co-investors415 Capital New Enterprise Associates (NEA)

剂泰科技 (METiS TechBio)

Biotech applying AI and quantum simulation to nanomaterials and innovative drug delivery (SEHK: 07666).

Co-investorsHongShan Capital Group

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Portfolio news

latest coverage across their companies

Cell therapy weekly: FDA approves glycogen storage disease type 1a gene therapy

Aurion Biotech · regmednet.com · Aug 20, 2026

Cohere Health Recognized in 2026 Gartner® Hype Cycle™ for U.S. Healthcare Payers for Fifth Consecutive Year - AOL

Cohere Health · aol.com · Aug 18, 2026

Shein’s $98.2 Bn Valuation Has Lost Its Shine, What Went Wrong?

Shine · outlookbusiness.com · Aug 17, 2026

White House Launches AI-Driven 'Gold Eagle' Vulnerability Coordination Initiative - SecurityWeek

Soon · securityweek.com · Jul 15, 2026

Audentes Therapeutics | San Francisco other | Altss

Audentes Therapeutics · altss.com · Jun 3, 2026

Reprieve Cardiovascular pilot study backs heart failure system

Reprieve Cardiovascular · massdevice.com · May 7, 2026

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline | Frontier Medicines

Frontier Medicines · frontiermeds.com · Aug 28, 2025

Top 3D Printing and Advanced Manufacturing Capital Raises in the U.S. – June 16th to 30th, 2025

Liquid Wire · castleplacement.com · Jul 9, 2025

Fund performance · per public LP disclosures

as of Jun 2024

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Deerfield Private Design Fund IVLPs: Florida State Board of Administration, Robert Wood Johnson Foundation	2007	—	7.9%	1.45x	0.11x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Public market activity · per SEC filings

what is this? ⓘ

59 insider ownership filings (Forms 3/4/5)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

What stage does Deerfield Management Company invest at?: Deerfield Management Company invests at the Growth, Late Stage stages.
What sectors does Deerfield Management Company focus on?: Deerfield Management Company focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
Where is Deerfield Management Company located?: Deerfield Management Company is headquartered in New York, US.
Does Deerfield Management Company lead rounds?: Deerfield Management Company has led 3 of the 3 rounds where its role is on record.

Images

Co-investors · 38

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 3

Acutus Medical Adelabio Audentes Therapeutics

$1M – $75M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 2

Element Science Encodia

$250K – $50M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 2

Encodia Homology Medicines

$50K – $250M

Flare Capital Partners

Flare Capital Partners is a healthcare technology-focused venture firm that partners with founders building companies to improve outcomes, lower costs, and reshape healthcare delivery.

Both backed · 2

Cohere Health Somatus

$1M – $10M

OUP (Osage University Partners)

OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.

Both backed · 2

Dracenpharma Homology Medicines

$1M – $20M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 1

Trivascular

$200K – $40M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

Both backed · 1

Frontier Medicines

$5M – $25M

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 1

Synthekine

$500K – $20M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

Both backed · 1

Neochord

$500K – $10M

Northpond Ventures

Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.

Both backed · 1

Encodia

$100K – $5M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 1

Homology Medicines

$100K – $4M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 1

Frontier Medicines

$1M – $15M

▶26 more co-investors

Foresite Capital Vivo Capital Andera Partners Optum Ventures Merck Global Health Innovation Fund Andreessen Horowitz Sequoia Capital Bain Capital Ventures Tiger Global Management Oak HC/FT C2 Investments Obvious Ventures Paradigm Haun Ventures Vast Ventures S32 Domain Associates City Light Novartis Venture Fund Frazier Healthcare Partners Roche Venture Fund RiverVest Venture Partners Franklin Templeton King River Capital APERTURE Venture Partners SteelSky Ventures

Firms observed investing alongside Deerfield Management Company, from public investor directories. Shared companies are the overlap with Deerfield Management Company's recorded portfolio.

Similar investors

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

$500K – $15M

Healthcare Venture Partners, Llc

Healthcare Venture Partners invests in innovative mid-to-late stage venture companies across the healthcare and life sciences industry, with particular emphasis on companies employing advanced technologies.

Ambix Venture Management, Llc

Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.

OneVentures

OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.

$3.3M – $13.2M